Management of heparin-induced thrombocytopenia

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 7, 2012, Pages 987-1006

  Jaax, Miriam E ^a   Greinacher, Andreas ^b  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

4T score; Argatroban; Bivalirudin; Danaparoid; Fondaparinux; Heparin; Heparin induced thrombocytopenia; Lepirudin; Thrombocytopenia; Thrombosis

Indexed keywords

ANTIVITAMIN K; APIXABAN; ARGATROBAN; DABIGATRAN ETEXILATE; DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; FC RECEPTOR IIA; FONDAPARINUX; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; HIRULOG; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT HIRUDIN; RIVAROXABAN; THROMBEXX; THROMBIN; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BONE MARROW DISEASE; CARDIOVASCULAR SURGERY; CLINICAL DECISION MAKING; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIABETIC KETOACIDOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PROTEIN BINDING; ECLAMPSIA; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HEPATOSPLENOMEGALY; HUMAN; IMMUNOASSAY; IMMUNOPATHOGENESIS; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LUNG EMBOLISM; NONHUMAN; OPTICAL DENSITY; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREGNANCY; PURPURA; RECEPTOR UPREGULATION; RECURRENT DISEASE; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTICOAGULANTS; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 84860182208     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.678834     Document Type: Review

References (155)

1. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011;9(Suppl 1):105-17
2. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-6
3. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia. 4th edition. Informa Healthcare USA; New York: 2007. p. 21-66
4. Greinacher A, Michels I, Liebenhoff U, et al. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 1993;84:711-16 (Pubitemid 23248066)
5. Horne MK III. Nonimmune heparin-platelet interactions: implications for the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia. 1st edition. Marcel Dekker, Inc.; New York: 2000. p. 113-26
6. Gao C, Boylan B, Fang J, et al. Heparin promotes platelet responsiveness by potentiating alphaIIbbeta3-mediated outside-in signaling. Blood 2011;117:4946-52
7. Kaplan KL, Broekman MJ, Chernoff A, et al. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood 1979;53:604-18 (Pubitemid 9154938)
8. Rucinski B, Niewiarowski S, James P, et al. Antiheparin proteins secreted by human platelets. purification, characterization, and radioimmunoassay. Blood 1979;53:47-62 (Pubitemid 9079257)
9. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-92 (Pubitemid 32372963)
10. Selleng K, Schutt A, Selleng S, et al. Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion 2010;50:32-9
11. Greinacher A, Ittermann T, Bagemuhl J, et al. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 2010;8:2025-31
12. Hursting MJ, Pai PJ, McCracken JE, et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010;134:774-80
13. Krauel K, Potschke C, Weber C, et al. Platelet factor 4 binds to bacteria-inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011;117:1370-8
14. Greinacher A, Holtfreter B, Krauel K, et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011;118:1395-401
15. Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of 'spontaneous' HIT? J Thromb Haemost 2008;6:1598-600
16. Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery 'spontaneous' HIT. J Thromb Haemost 2009;7:499-501
17. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008;121:632-6 (Pubitemid 351876183)
18. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5
19. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163:2518-24 (Pubitemid 37385796)
20. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003;101:3049-51 (Pubitemid 36857994)
21. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003;101:2955-9 (Pubitemid 36857979)
22. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001;185:148-52 (Pubitemid 32681809)
23. Lee D, Warkentin T. Frequency of heparin induced thrombocytopenia. In: Warkentin T, Greinacher A, editors. Heparin-Induced Thrombocytopenia. 4th edition. Informa Healthcare; New York: 2007. p. 67-116
24. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010;115:1797-803
25. Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006;108:2937-41
26. Warkentin TE, Crowther MA. When is HIT really HIT? Ann Thorac Surg 2007;83:21-3 (Pubitemid 44917871)
27. Lillo-Le LA, Boutouyrie P, Henc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004;2:1882-8 (Pubitemid 40192738)
28. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010;8:2642-50
29. Messmore HL, Fabbrini N, Bird ML, et al. Simple scoring system for early management of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2011;17:197-201
30. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-65
31. Lubenow N, Kempf R, Eichner A, et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002;122:37-42 (Pubitemid 34754140)
32. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:340S-80S (Pubitemid 351892970)
33. Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004;2:2133-7 (Pubitemid 40185772)
34. Weismann R, Tobin R. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg 1958;76:219-25
35. Roberts B, Rosato F, Rosato E. Heparin-a cause of arterial emboli? Surgery 1964;55:803-8
36. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973;136:409-16
37. WarkentinTE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005 May;127(5):1857-61 (Pubitemid 46218820)
38. Celoria GM, Steingart RH, Banson B, et al. Coumarin skin necrosis in a patient with heparin-induced thrombocytopenia: a case report. Angiology 1988;39:915-20
39. Cohen GR, Hall JC, Yeast JD, Field-Kriese D. Heparin-induced cutaneous necrosis in a postpartum patient. Obstet Gynecol 1988;72:498-9
40. Schindewolf M, Kroll H, Ackermann H, et al. Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 2010;8:1486-91
41. Pouplard C, Amiral J, Borg JY, et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999;111:700-6 (Pubitemid 29200959)
42. Pouplard C, Leroux D, Regina S, et al. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010;103:145-50
43. Legnani C, Cini M, Pili C, et al. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost 2010;104:402-9
44. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001;113:886-90 (Pubitemid 32634754)
45. Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997;54:196-201 (Pubitemid 27148257)
46. Pauzner R, Greinacher A, Selleng K, et al. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009;7:1070-4
47. Altuntas F, Matevosyan K, Burner J, et al. Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia. Eur J Haematol 2008;80:429-35 (Pubitemid 351503102)
48. Denys B, Devreese K. A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia: an update. Thromb Res 2009;124:642-3
49. Bakchoul T, Giptner A, Najaoui A, et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009;7:1260-5
50. Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008;6:1304-12 (Pubitemid 352016309)
51. Ruf KM, Bensadoun ES, Davis GA, et al. A clinical-laboratory algorithm incorporating optical density value to predict heparin-induced thrombocytopenia. Thromb Haemost 2011;105:553-9
52. Althaus K, Strobel U, Warkentin TE, Greinacher A. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res 2011;128:256-60
53. Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-51 (Pubitemid 24047336)
54. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008;100:678-84
55. Whitlatch NL, Kong DF, Metjian AD, et al. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 2010;116:1761-6
56. Bakchoul T, Giptner A, Bein G, et al. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 2011;127:345-8
57. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69:344-50 (Pubitemid 23103121)
58. Jy W, Mao WW, Horstman LL, et al. A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 1999;82:1255-9 (Pubitemid 29473788)
59. Morel-Kopp MC, Aboud M, Tan CW, et al. Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. Thromb Res 2010;125:e234-9
60. Elalamy I, Galea V, Hatmi M, Gerotziafas GT. Heparin-induced multiple electrode aggregometry: a potential tool for improvement of heparin-induced thrombocytopenia diagnosis. J Thromb Haemost 2009;7:1932-4
61. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005;3:2428-36 (Pubitemid 41727158)
62. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006;108:1492-6 (Pubitemid 44316113)
63. Lubenow N, Eichler P, Lietz T, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia:an analysis of three prospective studies. Blood 2004;104:3072-7 (Pubitemid 39507121)
64. Lindhoff-Last E, Piechottka GP, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 2000;100:55-60
65. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008;99:819-29 (Pubitemid 351705298)
66. Warkentin TE, Greinacher A, Craven S, et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005;94:958-64 (Pubitemid 41645934)
67. Kiser TH, Mann AM, Trujillo TC, Hassell KL. Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia. Am J Hematol 2011;86:267-72
68. Greinacher A, Janssens U, Berg G, et al. Lepirudin (Recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-93 (Pubitemid 29379746)
69. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80 (Pubitemid 29035960)
70. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51 (Pubitemid 30616845)
71. Cardenas GA, Deitcher SR. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. Mayo Clin Proc 2005;80:491-3 (Pubitemid 40471380)
72. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062-5 (Pubitemid 37337579)
73. Greinacher A, Eichler P, Albrecht D, et al. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003;101:2617-19 (Pubitemid 36857621)
74. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-35 (Pubitemid 27467766)
75. Boyce SW, Bandyk DF, Bartholomew JR, et al. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study. Am J Ther 2011;18:14-22
76. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91 (Pubitemid 20271869)
77. Augoustides JG. Update in hematology: heparin-induced thrombocytopenia and bivalirudin. J Cardiothorac Vasc Anesth 2011;25:371-5
78. Babuin L, Pengo V. Argatroban in the management of heparin-induced thrombocytopenia. Vasc Health Risk Manag 2010;6:813-19
79. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43 (Pubitemid 32328395)
80. Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 2007;24:489-99 (Pubitemid 46974912)
81. Boggio LN, Oza VM. Argatroban use in heparin-induced thrombocytopenia. Expert Opin Pharmacother 2008;9:1963-7
82. Ekbatani A, Asaro LR, Malinow AM. Anticoagulation with argatroban in a parturient with heparin-induced thrombocytopenia. Int J Obstet Anesth 2010;19:82-7
83. Gray A, Wallis DE, Hursting MJ, et al. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients. Clin Appl Thromb Hemost 2007;13:353-61 (Pubitemid 350114521)
84. Hursting MJ, Jang IK. Dosing patterns and outcomes in African American, Asian, and Hispanic patients with heparin-induced thrombocytopenia treated with argatroban. J Thromb Thrombolysis 2009;28:10-15
85. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2005;11:279-87 (Pubitemid 41022857)
86. Walenga JM, Drenth AF, Mayuga M, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Clin Appl Thromb Hemost 2008;14:325-31 (Pubitemid 351871948)
87. Le DT, Weibert RT, Sevilla BK, et al. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994;120:552-8 (Pubitemid 24091595)
88. Alatri A, Armstrong AE, Greinacher A, et al. Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy-an European Perspective. Thromb Res 2011; Epub ahead of print
89. Smythe MA, Koerber JM, Forsyth LL, et al. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacotherapy 2009;29:1073-81
90. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
91. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
92. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
93. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
94. Krauel K, Hackbarth C, Furll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012;119(5):1248-55
95. Danhof M, de BA, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992;22:73-84
96. Chong BH, Gallus AS, Cade JF, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost 2001;86:1170-5 (Pubitemid 33064563)
97. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001;85:950-7 (Pubitemid 32573742)
98. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: igG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998;80:292-7 (Pubitemid 28393626)
99. Krauel K, Furll B, Warkentin TE, et al. Heparin-induced thrombocytopenia-therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008;6:2160-7
100. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 1995;74:1468-73 (Pubitemid 26018663)
101. Greinacher A, Gopinadhan M, Gunther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006;26:2386-93 (Pubitemid 44465738)
102. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791-6 (Pubitemid 41739014)
103. Pouplard C, Couvret C, Regina S, Gruel Y. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 2005;3:2813-15 (Pubitemid 41819814)
104. Greinacher A. Immunogenic but Effective: the HIT-Fondaparinux brain puzzler. J Thromb Haemost 2011:Dec;9(12):2386-8
105. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40
106. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10
107. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-73
108. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702 (Pubitemid 37315006)
109. Wester JP, Leyte A, Oudemans-van Straaten HM, et al. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill. Neth J Med 2007;65:101-8 (Pubitemid 46487887)
110. Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005;93:999-1000 (Pubitemid 40691563)
111. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008;99:208-14
112. Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost 2010;16:663-7
113. Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 2011;9:2389-96
114. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
115. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15
116. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98
117. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-12 (Pubitemid 27465548)
118. Smythe MA, Warkentin TE, Stephens JL, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002;71:50-2 (Pubitemid 34988588)
119. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210-15 (Pubitemid 34118121)
120. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-17
121. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003;15:611-16 (Pubitemid 37409432)
122. Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-84
123. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia- alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 2002;28:439-46
124. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005;93:63-9 (Pubitemid 40124256)
125. Schindewolf M, Magnani HN, Lindhoff-Last E. Danaparoid in pregnancy in cases of heparin intolerance-use in 59 cases. Hamostaseologie 2007;27:89-97 (Pubitemid 46895864)
126. Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000;343:515 (Pubitemid 30646499)
127. Matsuo T, Kusano H, Wanaka K, et al. Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Hemost 2007;13:182-7 (Pubitemid 46548369)
128. Wanaka K, Matsuo T, Matsuo M, et al. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost 2010;8:616-18
129. Nuttall GA, Oliver WC Jr, Santrach PJ, et al. Patients with a history of type 2 heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg 2003;96:344-50 (Pubitemid 36125744)
130. Olinger GN, Hussey CV, Olive JA, Malik MI. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg 1984;87:673-7 (Pubitemid 14101247)
131. Selleng S, Lubenow N, Wollert HG, et al. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg 2001;71:1041-2 (Pubitemid 32210441)
132. Asmis LM, Segal JB, Plantinga LC, et al. Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost 2008;100:498-504
133. Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 1997;12:2750-5 (Pubitemid 27520712)
134. Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997;109:354-8 (Pubitemid 27267233)
135. O'Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 2003;16:61-7 (Pubitemid 37356769)
136. Fischer KG. Hemodialysis in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia. 3rd edition. Marcel Dekker; New York: 2004. p. 509-30
137. Chuang P, Parikh C, Reilly RF. A case review: anticoagulation in hemodialysis patients with heparin-induced thrombocytopenia. Am J Nephrol 2001;21:226-31 (Pubitemid 32620200)
138. Unver B, Sunder-Plassmann G, Horl WH, Apsner R. Long-term citrate anticoagulation for high-flux haemodialysis in a patient with heparin-induced thrombocytopenia type 2. Acta Med Austriaca 2002;29:146-8 (Pubitemid 35015270)
139. Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int 2007;11:178-89
140. Trossaert M, Gaillard A, Commin PL, et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101:653-5 (Pubitemid 28308512)
141. Everett BM, Yeh R, Foo SY, et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 2007;83:592-7 (Pubitemid 46135456)
142. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530-6 (Pubitemid 29228283)
143. Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 2010;8:30-6
144. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8 (Pubitemid 30661052)
145. Demma LJ, Levy JH. Diagnosing heparin-induced thrombocytopenia in cardiac surgical patients: not as easy as you think. Anesth Analg 2011;112:747-9
146. Selleng S, Haneya A, Hirt S, et al. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood 2008;112:4024-7
147. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-31
148. Greinacher A, Alban S, Dummel V, et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995;74:886-92
149. Visentin GP, Moghaddam M, Beery SE, et al. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/ thrombosis. J Lab Clin Med 2001;138:22-31 (Pubitemid 32589199)
150. Alban S, Franz G. Gas-liquid chromatography-mass spectrometry analysis of anticoagulant active curdlan sulfates. Semin Thromb Hemost 1994;20:152-8 (Pubitemid 24263664)
151. Rosenthal MA, Rischin D, McArthur G, et al. Treatment with the novel
152. Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 2009;8:129-44
153. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2:148-57
154. Greinacher A, Lubenow N, Hinz P, Ekkernkamp A. Heparin-induzierte thrombozytopenie. Deutsches Arzteblatt 2003;100:A2220-9
155. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007;35:1165-76 (Pubitemid 46598970)